Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. Sep 09, 2020, 07:00am EDT This article is more than 5 years old. Chris Gibson, ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Bayer Aktiengesellschaft BAYRY entered into a strategic collaboration agreement with Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery for the treatment of ...
June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...
Recursion Inc.’s combination of machine learning and artificial intelligence, coupled to its wet lab work, caught Bayer AG’s attention so solidly that its investment unit, Leaps by Bayer, led the ...
The biotech entered 2025 with around 800 employees. (iStock / Getty Images Plus) Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining ...
Recursion—the computational capacity to embed elements within elements of the same kind—has been lauded as the intellectual cornerstone of language, tool use and mathematics. A multi-institutional ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results